TEVA PHARMACEUTICAL INDS LTD shareholders Q3 2023

TEVA PHARMACEUTICAL INDS LTD's ticker is TEVA and the CUSIP is 881624209. A total of 429 filers reported holding TEVA PHARMACEUTICAL INDS LTD in Q3 2023. The put-call ratio across all filers is 0.51 and the average weighting 0.4%.

TEVA PHARMACEUTICAL INDS LTD shareholders Q3 2023
NameSharesValueWeighting ↓
Ion Asset Management Ltd. 38,822,516$395,989,66340.91%
Lingotto Investment Management LLP 33,849,856$345,268,53118.52%
SPHERA FUNDS MANAGEMENT LTD. 5,013,800$51,140,7599.32%
Tri Locum Partners LP 2,632,893$26,855,5098.59%
Rubric Capital Management LP 19,000,000$193,800,0007.27%
Slate Path Capital LP 23,844,000$243,208,8006.78%
Phoenix Holdings Ltd. 34,481,692$351,712,8396.45%
Eversept Partners, LP 6,952,085$70,911,2676.00%
Migdal Insurance & Financial Holdings Ltd. 27,059,540$276,0005.90%
Affinity Asset Advisors, LLC 2,000,000$20,400,0005.74%
Soleus Capital Management, L.P. 6,052,164$61,732,0735.70%
BRIDGER MANAGEMENT, LLC 1,500,000$15,300,0005.63%
Harel Insurance Investments & Financial Services Ltd. 27,711,340$282,6565.58%
Tejara Capital Ltd 822,495$8,389,4494.76%
Monaco Asset Management SAM 1,525,000$15,555,0004.61%
Clal Insurance Enterprises Holdings Ltd 30,614,669$312,2704.35%
DSC Advisors, L.P. 292,500$2,983,5003.83%
Camber Capital Management LP 10,150,000$103,5303.41%
Affinity Asset Advisors, LLC 1,100,000$11,220,0003.16%
SOUND SHORE MANAGEMENT INC /CT/ 7,920,712$80,791,2623.09%
About TEVA PHARMACEUTICAL INDS LTD

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company that specializes in the development, production, and marketing of generic and specialty medicines. The company is headquartered in Israel and has operations in over 60 countries worldwide.

Teva has a diverse portfolio of products that includes treatments for a wide range of medical conditions, including respiratory, neurological, and oncological diseases. The company is also a leading producer of generic drugs, which are more affordable alternatives to brand-name medications.

In recent years, Teva has faced a number of challenges, including increased competition in the generic drug market and a decline in sales of its flagship product, Copaxone, which is used to treat multiple sclerosis. However, the company has taken steps to address these issues, including restructuring its operations and investing in research and development to bring new products to market.

Despite these challenges, Teva remains a major player in the pharmaceutical industry, with a strong global presence and a commitment to improving the health and well-being of patients around the world. As the company continues to evolve and adapt to changing market conditions, it will be interesting to see what the future holds for this innovative and dynamic organization.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

External links

This page lists TEVA PHARMACEUTICAL INDS LTD's shareholders in Q3 2023. To view TEVA PHARMACEUTICAL INDS LTD's shareholder history, click here.